Klaus Eckhof joins Classic Minerals in gold standard appointment


Published 19-SEP-2019 14:59 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

One of the most respected figures in the mining industry, Klaus Eckhof, has today joined Classic Minerals (ASX:CLZ) as a Corporate and Technical Advisor.

Eckhof will join Classic Minerals effective immediately and will be advising the company on its Forrestania Gold Project generally and on the Kat Gap Project in particular.

Mr. Eckhof has extensive international experience and will become an invaluable member of the CLZ team.

This is somewhat of a coup for Classic with CLZ chairman John Lester saying that he “was delighted that Klaus has accepted to join Classic Minerals as a trusted and capable advisor who brings a new and exciting vision to the Board and Management of Classic as Dean (CEO Dean Goodwin) progresses with extensional drilling at Kat Gap.

“We are privileged that Klaus with his integrity, dynamism and international network has agreed to guide, direct and enhance the vision of Classic Minerals Limited.”

Klaus Eckhof.

As a geologist with more than 25 years of experience, Mr Eckhof has developed mineral deposits throughout the globe.

In a long career, he has plied his expertise for Mount Edon Gold Mines Ltd as Business Development Manager. Mount Edon was acquired by Canadian mining company Teck for $158 million.

Spinifex Gold Ltd and Lafayette Mining Ltd were founded by Mr Eckhof in 1994. Both companies successfully delineated gold and base metal deposits.

Then in late 2003, Mr.Eckhof famously founded Moto Goldmines which acquired the Moto Gold Project in the Democratic Republic of the Congo (DRC).

More than 20million ounces of gold were delineated and a feasibility study delivered within four years.

Eckhof grew the company from 4 cents to $4 per share — a 9,900% return and given its success, Moto Goldmines attracted the attention of Randgold Resources, who poured first gold in September 2013. Randgold conducted a $502 million takeover of Moto on the back of the 17Moz Kibali gold deposit.

Not one to rest on his laurels, Mr Eckhof was also formerly Executive Chairman of AVZ Minerals Ltd. (ASX: AVZ), a mineral exploration company focused on developing the Manono Project, located in the south of the DRC.

The Manono Project has the largest JORC Measured and Indicated Lithium hard rock resource globally and Mr Eckhof was instrumental in identifying the Bisie Tin deposit located in the DRC, one of the largest and most significant tin deposits in the world.

Manono was acquired by TSX-V listed Alphamin Resources Corp.

CLZ should greatly benefit from Mr Eckhof’s expertise as he adds technical and international fund-raising clout.

Classic is hoping to expand its exploration programs at Forrestania generally and on the Kat Gap Project in particular, with Mr Eckhof responsible for marketing the company and its projects throughout North America and Europe.

Classic has agreed to issue performance rights to Mr Eckhof in lieu of any cash-based remuneration. Full remuneration details can be found intoday's ASX announcement.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free